CN111936487B - 用于治疗激酶依赖性病症的化合物 - Google Patents

用于治疗激酶依赖性病症的化合物 Download PDF

Info

Publication number
CN111936487B
CN111936487B CN201980021651.XA CN201980021651A CN111936487B CN 111936487 B CN111936487 B CN 111936487B CN 201980021651 A CN201980021651 A CN 201980021651A CN 111936487 B CN111936487 B CN 111936487B
Authority
CN
China
Prior art keywords
alkyl
compound
alkylene
cycloalkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980021651.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN111936487A (zh
Inventor
L·C·班宁
M·别伊
蒋发明
王勇
许维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of CN111936487A publication Critical patent/CN111936487A/zh
Application granted granted Critical
Publication of CN111936487B publication Critical patent/CN111936487B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201980021651.XA 2018-01-26 2019-01-25 用于治疗激酶依赖性病症的化合物 Active CN111936487B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862622702P 2018-01-26 2018-01-26
US201862622626P 2018-01-26 2018-01-26
US62/622,702 2018-01-26
US62/622,626 2018-01-26
PCT/US2019/015296 WO2019148043A1 (en) 2018-01-26 2019-01-25 Compounds for the treatment of kinase-dependent disorders

Publications (2)

Publication Number Publication Date
CN111936487A CN111936487A (zh) 2020-11-13
CN111936487B true CN111936487B (zh) 2024-07-09

Family

ID=65685938

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980021651.XA Active CN111936487B (zh) 2018-01-26 2019-01-25 用于治疗激酶依赖性病症的化合物

Country Status (8)

Country Link
US (2) US11673897B2 (https=)
EP (1) EP3743417A1 (https=)
JP (1) JP7480048B2 (https=)
CN (1) CN111936487B (https=)
AU (1) AU2019212800B2 (https=)
CA (1) CA3088198A1 (https=)
MA (1) MA51679A (https=)
WO (1) WO2019148043A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117402114A (zh) * 2018-01-26 2024-01-16 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
CN115461328B (zh) 2020-04-30 2025-11-07 埃克塞里艾克西斯公司 用于制备激酶抑制剂的方法
TW202241862A (zh) * 2021-02-01 2022-11-01 大陸商江蘇恆瑞醫藥股份有限公司 二甲醯胺類化合物、其製備方法及其在醫藥上的應用
MX2023009560A (es) * 2021-02-17 2023-10-25 Springworks Therapeutics Inc Solidos cristalinos del inhibidor de mek n-((r)-2,3-dihidroxipropo xi)-3,4-difluoro-2-(2-fluoro-4-yodo-fenilamino)-benzamida y sus usos.
WO2026074526A1 (en) * 2024-10-04 2026-04-09 Hetero Labs Limited 1,2-dicarboxamide compounds as kinase inhibitors

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030140A2 (en) * 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and methods of use
WO2007103308A2 (en) * 2006-03-07 2007-09-13 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
CN101605540A (zh) * 2006-12-14 2009-12-16 埃克塞利希斯股份有限公司 使用mek抑制剂的方法
WO2010045095A1 (en) * 2008-10-14 2010-04-22 Ning Xi Compounds and methods of use
CN102256493A (zh) * 2008-10-29 2011-11-23 迪赛孚尔制药有限公司 表现出抗癌活性和抗增殖活性的环丙烷酰胺及其类似物
WO2016184434A1 (zh) * 2015-05-21 2016-11-24 中国科学院上海药物研究所 一种吡啶并氮杂环化合物及其制备方法和用途
WO2018153293A1 (zh) * 2017-02-27 2018-08-30 北京赛特明强医药科技有限公司 二噁烷并喹唑啉与二噁烷并喹啉类化合物及其制备方法与应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508537D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
EA001595B1 (ru) 1996-04-12 2001-06-25 Варнер-Ламберт Компани Необратимые ингибиторы тирозинкиназ
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
AU9598601A (en) 2000-10-20 2002-04-29 Eisai Co Ltd Nitrogenous aromatic ring compounds
US8466143B2 (en) * 2003-07-23 2013-06-18 Exelixis, Inc. Azepine derivatives as pharmaceutical agents
CA2604238C (en) 2005-04-15 2015-07-07 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
AU2006309551B2 (en) 2005-11-07 2012-04-19 Eisai R & D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
EP2213686A1 (en) 2009-01-28 2010-08-04 Externautics S.p.A. Tumor markers and methods of use thereof
EP2214019A1 (en) 2009-01-28 2010-08-04 Externautics S.p.A. Tumor markers and methods of use thereof
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2494351B1 (en) 2009-10-26 2016-06-08 Externautics S.p.A. Colon and rectal tumor markers and methods of use thereof
US8921058B2 (en) 2009-10-26 2014-12-30 Externautics Spa Prostate tumor markers and methods of use thereof
WO2011051277A1 (en) 2009-10-26 2011-05-05 Externautics S.P.A. Breast tumor markers and methods of use thereof
US10288617B2 (en) 2009-10-26 2019-05-14 Externautics Spa Ovary tumor markers and methods of use thereof
WO2011051278A1 (en) 2009-10-26 2011-05-05 Externautics S.P.A. Lung tumor markers and methods of use thereof
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
EP2383578A1 (en) 2010-04-30 2011-11-02 Externautics S.p.A. Tumor marker and methods of use thereof
ES2598530T3 (es) * 2010-07-14 2017-01-27 Betta Pharmaceuticals Co., Ltd. Nuevos derivados heterocíclicos condensados útiles como inhibidores de la tirosina quinasa c-Met
US8664244B2 (en) 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
CN102093421B (zh) 2011-01-28 2014-07-02 北京康辰药业有限公司 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
CN102408411B (zh) 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
SMT202100065T1 (it) 2013-05-02 2021-03-15 Anaptysbio Inc Anticorpi diretti contro la proteina della morte programmata (pd-1)
EP3008086A2 (en) 2013-06-14 2016-04-20 Externautics S.p.A. Tumor marker, monoclonal antibodies and methods of use thereof
IL292510A (en) 2013-11-05 2022-06-01 Cognate Bioservices Inc Combinations of checkpoint inhibitors and therapeutics to treat cancer
UA121655C2 (uk) * 2014-04-25 2020-07-10 Екселіксіс, Інк. Спосіб лікування аденокарциноми легень
CN104817497B (zh) 2015-03-20 2017-03-08 南京众睿缘生物科技有限公司 一种炔代喹啉衍生物及其制备方法和用途
US20170342033A1 (en) 2015-06-29 2017-11-30 Ontogenesis, Llc Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
US20180009758A1 (en) 2015-06-29 2018-01-11 Ontogenesis, Llc Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
CN105797123A (zh) 2016-05-18 2016-07-27 王超 一种治疗不孕不育的中药组合物
CN106400155A (zh) 2016-08-31 2017-02-15 飞佛特种纺织品（宁波）有限公司 一种防老化阳光面料
CN107235896B (zh) 2016-09-13 2019-11-05 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂及其应用
CN110049969A (zh) 2017-02-07 2019-07-23 恩瑞生物医药科技（上海）有限公司 喹啉类化合物、其制备方法及其医药用途
SG11202005719UA (en) 2017-12-20 2020-07-29 Angex Pharmaceutical Inc Carbamate and urea compounds as multikinase inhibitors
CR20250117A (es) 2018-01-26 2025-05-09 Exelixis Inc COMPUESTOS PARA EL TRATAMIENTO DE TRASTORNOS DEPENDIENTES DE CINASAS (Divisional 2020-0355)
CN117402114A (zh) 2018-01-26 2024-01-16 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030140A2 (en) * 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and methods of use
WO2007103308A2 (en) * 2006-03-07 2007-09-13 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
CN101605540A (zh) * 2006-12-14 2009-12-16 埃克塞利希斯股份有限公司 使用mek抑制剂的方法
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
WO2010045095A1 (en) * 2008-10-14 2010-04-22 Ning Xi Compounds and methods of use
CN102256493A (zh) * 2008-10-29 2011-11-23 迪赛孚尔制药有限公司 表现出抗癌活性和抗增殖活性的环丙烷酰胺及其类似物
WO2016184434A1 (zh) * 2015-05-21 2016-11-24 中国科学院上海药物研究所 一种吡啶并氮杂环化合物及其制备方法和用途
WO2018153293A1 (zh) * 2017-02-27 2018-08-30 北京赛特明强医药科技有限公司 二噁烷并喹唑啉与二噁烷并喹啉类化合物及其制备方法与应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STN.STN.《STN》.2000, *

Also Published As

Publication number Publication date
WO2019148043A1 (en) 2019-08-01
AU2019212800B2 (en) 2024-05-23
MA51679A (fr) 2020-12-02
US11673897B2 (en) 2023-06-13
JP7480048B2 (ja) 2024-05-09
CN111936487A (zh) 2020-11-13
JP2021511357A (ja) 2021-05-06
EP3743417A1 (en) 2020-12-02
US20210032263A1 (en) 2021-02-04
CA3088198A1 (en) 2019-08-01
AU2019212800A1 (en) 2020-08-20
US20240150371A1 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
CN111757735B (zh) 用于治疗激酶依赖性病症的化合物
JP7596427B2 (ja) キナーゼ依存的障害を処置するための化合物
CN111936487B (zh) 用于治疗激酶依赖性病症的化合物
HK40106338A (zh) 用於治疗激酶依赖性病症的化合物
HK40106340A (zh) 用於治疗激酶依赖性病症的化合物
HK40043088B (zh) 用於治疗激酶依赖性病症的化合物
HK40106337A (zh) 用於治疗激酶依赖性病症的化合物
HK40106339A (zh) 用於治疗激酶依赖性病症的化合物
HK40046174B (zh) 用於治疗激酶依赖性病症的化合物
HK40043088A (en) Compounds for the treatment of kinase-dependent disorders
HK40039571B (zh) 用於治疗激酶依赖性病症的化合物
BR112020015199B1 (pt) Composto, composição farmacêutica e uso dos mesmos para tratar distúrbios dependentes de quinase

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40043088

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant